Journal: Molecular and cellular endocrinology

Article Title: Exogenous Thyroxine Increases Cardiac GLUT4 Translocation in Insulin Resistant OLETF Rats.

doi: 10.1016/j.mce.2024.112254

Figure Lengend Snippet: Figure 4. Thyroid hormone profile in heart, T4 increased THRB1 in cytosol. Mean ± SD values for (A) Monocarboxylate transporter 8 (MCT8) protein expression, (B) deiodinase 2 (DIO2) protein expression, (C) thyroid hormone receptor beta 1 (THRB1) protein expression, (D) nuclear thyroid hormone receptor alpha (THRa) protein expression and (E) representative blot of LETO, LETO + T4, OLETF, and OLETF + T4 rats (n=6-7) PS, ponceau stain. *, Significant difference from LETO p<0.05. &, Significant difference from OLETF p<0.05. $, Significant difference from LETO + T4 p<0.05. #, Significant difference from OLETF + T4 p<0.05.

Article Snippet: 126 Membranes were incubated with primary antibodies against GLUT4 (Abcam, ab33780, Boston, 127 MA, USA), pS488-GLUT4 (Abcam, ab188317, Boston, MA, USA), insulin receptor (IR) (Cell 128 Signaling Technology, 3025S, USA), insulin receptor substrate (IRS) 1 + IRS 2 (abcam, ab40777, 129 Boston, MA, USA), phosphoinositide 3-kinases p110 (PI3K)p110 (Proteintech, 67071-1-Ig, 130 Rosemont, IL, USA), protein kinase B (AKT) (Cell Signaling Technology, 9272S, USA), p-AKT (Cell 131 Jo urn al Pr e-p roo f REVISED Manuscript (text UNmarked) 7 Signaling Technology, 4060S, USA), anti-AMPK alpha 1 (phospho T183) + AMPK alpha 2 (phospho 132 T172) (Abcam, ab133448, Boston, MA, USA), AKT substrate 160 (AS160) (C69A7) (Cell Signaling 133 Technology, 2670S, USA), Phospho-AS160 (Thr642) (D27E6) (Cell Signaling Technology, 8881S, 134 USA), hexokinase 2 (Proteintech, 22029-1-AP, Rosemont, IL, USA), phosphofructokinase muscle 135 type (PFKM) (Abcam, ab154804, Boston, MA, USA), monocarboxylate transporter 8 (MCT8) 136 (Abcam, ab302706, Boston, MA, USA), Type II iodothyronine deiodinase (DIO2) (Proteintech, 137 26513-1-AP, Rosemont, IL, USA), thyroid hormone receptor β (TRβ1) (Abcam, ab180612, Boston, 138 MA, USA), thyroid hormone receptor alpha (THRa) (Proteintech, 66703-1-Ig, Rosemont, IL, USA), 139 the fatty acid transporter, cluster of differentiation 36 (CD36) (Thermo Fisher, PA1-16813, 140 Houston, TX, USA), fatty acid transporter (FATP1) (MyBioSource, MBS9384813, San Diego, CA, 141 USA), carnitine palmitoyltransferase 2 (CPT2) (Invitrogen, PA5-30420, Waltham, MA, USA), acyl-142 coA oxidase 1 (ACOX) (Thermo Fisher, PA5-76341, USA), acetyl-coA carboxylase 1 (ACC) (Cell 143 Signaling Technology, 3662S, USA), diacylglycerol O-acyltransferase 1 (DGAT1) (Thermo Fisher, 144 PA5-79150, Houston, TX, USA), and glycerol-3-phosphate acyltransferase (GPAM) (abcam, 145 ab69990, Boston, MA, USA).

Techniques: Expressing, Staining

Journal: Atherosclerosis

Article Title: Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization.

doi: 10.1016/j.atherosclerosis.2025.119110

Figure Lengend Snippet: Fig. 4. Cell-type specific expression in the aortic valve tissue for the proteins with PPH4 > 0.8. (A) Uniform manifold of approximation and projection clustering map of the aortic valves from 2 healthy donors and 4 patients with CAVD. (B–H) Expression patterns of ANGPTL4, PCSK9, ITGAV, CTSB, GNPTG, and FURIN in each aortic valve cell type. Red dots represent cells expressing the corresponding proteins. VIC, valvular interstitial cell; VDSC, valve-derived stromal cell; VEC, valvular endothelial cell. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: The primary antibodies used were as follows: ANGPTL4 (cat #18374-1-AP, Proteintech, 1:250); ITGAV (cat # 27096- 1-AP, Proteintech, 1:500).

Techniques: Expressing, Derivative Assay

Journal: Atherosclerosis

Article Title: Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization.

doi: 10.1016/j.atherosclerosis.2025.119110

Figure Lengend Snippet: Fig. 5. Upregulation of ANGPTL4 and ITGAV in osteogenic VICs and calcific aortic valves. (A) Volcano plot showing differentially expressed genes between VICs cultured in the growth medium and the osteogenic medium. The x-axis represents the fold change, while the y-axis shows the q-value. (B) Representative WB image of ANGPTL4, ITGAV, and ALP in VICs. (C) Quantification of protein levels from WB analysis. (D) Representative immunofluorescence images showing ANGPTL4 and ITGAV expression in human aortic valves. (E) Quantification of mean fluorescence intensity for ANGPTL4 and ITGAV. **p < 0.01, ***p < 0.001 vs. GM or Non-CAVD. GM, growth medium; OM, osteogenic medium.

Article Snippet: The primary antibodies used were as follows: ANGPTL4 (cat #18374-1-AP, Proteintech, 1:250); ITGAV (cat # 27096- 1-AP, Proteintech, 1:500).

Techniques: Cell Culture, Immunofluorescence, Expressing, Fluorescence